Abstract
Angiotensin-converting enzyme 2 (ACE2) is an enzymatically active homologue of angiotensin-converting enzyme that degrades angiotensin I, angiotensin II, and other peptides. Recent studies have shown that under pathologic conditions, ACE2 expression in the kidney is altered. In this review, we briefly summarize recent studies dealing with pharmacologic interventions that modulate ACE2 expression. ACE2 amplification may have a potential therapeutic role for kidney disease and hypertension.
References and Recommended Reading
Danilczyk U, Penninger JM: Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 2006, 98:463–471.
Tipnis SR, Hooper NM, Hyde R, et al.: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000, 275:332 38–332 43.
Donoghue M, Hsieh F, Baronas E, et al.: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 2000, 87:E1–E9.
Crackower MA, Sarao R, Oudit GY, et al.: Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417:822–828.
Xie X, Chen J, Wang X, et al.: Age-and gender-related difference of ACE2 expression in rat lung. Life Sci 2006, 78:2166–2171.
Valdes G, Neves LA, Anton L, et al.: Distribution of angiotensin-(1–7) and ACE2 in human placentas of normal and pathological pregnancies. Placenta 2006, 27:200–207.
Paizis G, Tikellis C, Cooper ME, et al.: Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 2005, 54:1790–1796.
Imai Y, Kuba K, Rao S, et al.: Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005, 436:112–116.
Hamming I, Timens W, Bulthuis ML, et al.: Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004, 203:631–637.
Doobay MF, Talman LS, Obr TD, et al.: Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007, 292:R373–R381.
Batlle D, Soler MJ, Wysocki J: New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2—a potential target for treatment of hypertension and diabetic nephropathy. Curr Opin Nephrol Hypertens 2008, 17:250–257.
Soler MJ, Wysocki J, Batlle D: ACE2 and the kidney. Exp Physiol 2008, 93:549–553.
Soler MJ, Wysocki J, Ye M, et al.: ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 2007, 72:614–623.
Tikellis C, Cooper ME, Bialkowski K, et al.: Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney Int 2006, 70:34–41.
Wysocki J, Ye M, Soler MJ, et al.: ACE and ACE2 activity in diabetic mice. Diabetes 2006, 55:2132–2139.
Ye M, Wysocki J, William J, et al.: Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006, 17:3067–3075.
Zhong JC, Huang DY, Yang YM, et al.: Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension 2004, 44:907–912.
Leehey DJ, Singh AK, Bast JP, et al.: Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats. Transl Res 2008, 151:208–216.
Ye M, Wysocki J, Naaz P, et al.: Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 2004, 43:1120–1125.
Wysocki J, Gonzalez-Pacheco FR, Batlle D: Angiotensin-converting enzyme 2: possible role in hypertension and kidney disease. Curr Hypertens Rep 2008, 10:70–77.
Wong DW, Oudit GY, Reich H, et al.: Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 2007, 171:438–451.
Brosnihan KB, Neves LA, Joyner J, et al.: Enhanced renal immunocytochemical expression of ANG-(1–7) and ACE2 during pregnancy. Hypertension 2003, 42:749–753.
de Lang A, Osterhaus AD, Haagmans BL: Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology 2006, 353:474–481.
Keidar S, Gamliel-Lazarovich A, Kaplan M, et al.: Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 2005, 97:946–953.
Gallagher PE, Chappell MC, Ferrario CM, Tallant EA: Distinct roles for ANG II and ANG-(1–7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol 2006, 290:C420–C426.
Koka V, Huang XR, Chung AC, et al.: Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 2008, 172:1174–1183.
Zulli A, Rai S, Buxton BF, et al.: Co-localization of angiotensin-converting enzyme 2-, octomer-4-and CD34-positive cells in rabbit atherosclerotic plaques. Exp Physiol 2008, 93:564–569.
Ji H, Menini S, Zheng W, et al.: Role of angiotensin-converting enzyme 2 and angiotensin(1–7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension. Exp Physiol 2008, 93:648–657.
Gupta A, Rhodes GJ, Berg DT, et al.: Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2. Am J Physiol Renal Physiol 2007, 293:F245–F254.
Soler MJ, Wysocki J, William J, et al.: ACE2 is preferentially localized in the tunica media layer in renal vasculature and its expression increases after administration of a type 1 receptor antagonist [abstract]. Hypertension 2006, 48:E25–E103 LB 12.
Ocaranza MP, Godoy I, Jalil JE, et al.: Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 2006, 48:572–578.
Igase M, Strawn WB, Gallagher PE, et al.: Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1–7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005, 289:H1013–H1019.
Ferrario CM, Jessup J, Gallagher PE, et al.: Effects of renin-angiotensin system blockade on renal angiotensin-(1–7) forming enzymes and receptors. Kidney Int 2005, 68:2189–2196.
Takeda Y, Zhu A, Yoneda T, et al.: Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2007, 20:1119–1124.
Jessup JA, Gallagher PE, Averill DB, et al.: Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 2006, 291:H2166–H2172.
Agata J, Ura N, Yoshida H, et al.: Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006, 29:865–874.
Whaley-Connell AT, Chowdhury NA, Hayden MR, et al.: Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2006, 291:F1308–F1314.
Yamamoto K, Ohishi M, Katsuya T, et al.: Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006, 47:718–726.
Oudit GY, Kassiri Z, Patel MP, et al.: Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 2007, 75:29–39.
Benson SC, Pershadsingh HA, Ho CI, et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993–1002.
Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 2005, 64:476–478.
Kobayashi N, Ohno T, Yoshida K, et al.: Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 2008, 21:576–581.
Tikellis C, Bialkowski K, Pete J, et al.: ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 2008, 57:1018–1025.
Hernandez Prada JA, Ferreira AJ, Katovich MJ, et al.: Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008, 51:1312–1317.
Ye M, Wysocki J, Rodriguez E, et al.: Recombinant ACE2 attenuates angiotensin II induced hypertension [abstract]. Hypertension 2007, 50:e75–e155.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Soler, M.J., Barrios, C., Oliva, R. et al. Pharmacologic modulation of ACE2 expression. Current Science Inc 10, 410–414 (2008). https://doi.org/10.1007/s11906-008-0076-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-008-0076-0
Keywords
- Telmisartan
- Olmesartan
- Eplerenone
- ACE2 Activity
- ACE2 Protein